Please login to the form below

Addressing the Gendered Health Data Gap

The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.

When thinking about personalised treatment today, we think of targeted cancer treatments, or gene therapies. Treatments that are designed for small subgroups of diseases or people and which are more effective because they are designed specifically for what they intend to do.

Whilst we have made huge strides in improving treatment for some of these conditions, it seems we are still missing a trick. Without the need for technological advances or medical innovation, we could better design our health systems and our treatments for 50% of the patient population. It seems an obvious place to start.

Everything created in our world has been thought through in terms of design: how high to put the shelving units in the supermarket, the temperature of your office and the safety specifications of your car. In making these decisions engineers and designers look at data to understand the optimal approach.

However, this only works when the data is representative of the people the design is aiming to serve, and all too often it isn’t. Women are often underrepresented or missing from these data sets resulting in a world that has been designed for men as default. This is also true of our healthcare systems; our clinical trials, our diagnostic approaches and our treatment options, all typically have men as the default.

Take heart attacks for example, the British Heart Foundation found women are 50% more likely to be misdiagnosed following a heart attack. One of the routine tests to diagnose a heart attack is the troponin test used to identify damage to heart cells. However, it was found that the expected ‘normal’ limits set were those that were normal for men as the default, leading to a higher incidence of women’s heart attacks going misdiagnosed. Women were missing from the data sets used to build the limits, and therefore the test becomes much less effective for women.

By using a more sensitive test and altering the expected limits to be appropriate for women, the number of women diagnosed with a heart attack doubled – women who otherwise would not have received a diagnosis, leading to delay in treatment and therefore worse outcomes overall.

As Caroline Cirado Perez points out in her book Invisible Women, this isn’t some malicious attempt to exclude half of the population from the world we design, it is just a consequence of non-representation. By not including women in the data sets used we continue to build systems with men as the default and this can have serious, and potentially deadly, consequences.

However, as the example above shows, the potential for positive change can be huge. By simply splitting data sets by sex, we can quickly and easily identify missing data, and find opportunities where addressing these could make a big impact to addressing gendered health inequalities. If this had been done in setting heart attack limits it would have become clear that there should be different levels for men and women.

The WHO’s Global Health Statistics were disaggregated by sex for the first time in 2019. So, whilst it’s a wonder that this wasn’t considered before 2019, it’s a step in the right direction. It’s a starting line.

In the UK, the Government are looking to address gendered health inequalities, bringing forward England’s first Women’s Health Strategy. Putting aside the fact that even the need for this clearly shows that women’s health isn’t covered by ‘health’ in itself, it is a great opportunity to address the gendered health data gap.

As we start to put more and more faith in data, the responsibility to make sure this data is representative of both women and men becomes stronger. A key part of the Women’s Health Strategy should be on ensuring women are included in the data sets used in health system design, clinical trials and disease management and also that the data is disaggregated to identify gendered differences.

Disaggregating these data has clear benefits for the female 50% of the population but it also has benefits for other groups; race, ethnicity and socioeconomic factors should all be taken into account too.

Not only will this ensure we are designing systems for all the people that will use them, but it will also mean we are able to see solutions we wouldn’t otherwise and uncover things that don’t intuitively feel true, or that we or others would never think to consider. For example, despite pregnant women being at increased risk from COVID-19, it took a campaigning group for them to gain access to the vaccine, a result that benefits the health system as a whole. At a time when the health system is recovering from the COVID-19 pandemic, finding smart, effective solutions to improving the health of the nation is paramount.

It is fascinating to think of the breakthroughs we may be able to take in medicine simply by challenging ourselves to ask the right questions and look at the right data. All of us are designers in our everyday lives, whether designing disease awareness campaigns or creating policy asks. We can all take a better look at the insights and data we use to inform our decisions and design, but we should also feel buoyed by the impact that we can have in making the world one that works for everyone.

9th June 2021

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

What do NHS changes and the Life Sciences Vision mean for medicines?
With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.
Hanover Communications
Addressing the Gendered Health Data Gap
The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.
Hanover Communications
Greener healthcare - a shared challenge
At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.
Hanover Communications
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications